SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta is trending as a potential solution to increase transaction speeds and enhance regulatory compliance in blockchain, with some community members suggesting it could complement larger crypto projects like NVDA, SUI, and BTC. Its focus on institutional financial infrastructure and integrations with companies like Stripe are also key talking points. However, some users express concern regarding the project.

Power & Digital Infrastructure Acquisition Corp. operates as a blank check company. The firm engages in seeking a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses or entities. The company was founded on December 29, 2020 and is headquartered in Chicago, IL.

Core Scientific Inc - Ordinary Shares - New

Core Scientific Inc

Core Scientific (CORZ) is trending as investors digest the implications of a failed merger, with the community now speculating on new customer announcements and financing opportunities. Bullish sentiment suggests the company is undervalued, especially given its AI infrastructure and power pipeline, leading to discussions about potential upside into 2026. Some are hopeful for new deals that could drive the stock higher, while others are critical of management's strategy.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending as investors discuss the potential impact of a move to the Nasdaq exchange and speculate about upcoming OEM partnerships, particularly with the inauguration of the Eagle Line facility approaching in February 2026. The community's focus is on the company's technology, scaling roadmap, and anticipated announcements, with bullish investors expressing confidence in QuantumScape's long-term potential in the solid-state battery market.

Avalanche is a high throughput smart contract blockchain platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche (AVAX) is trending as discussions highlight its subnet architecture and DeFi presence, but also contrasting it with Keeta, a compliance-focused Layer 1 solution. The community is actively weighing the potential of each platform, particularly regarding institutional adoption and financial infrastructure. Mentions of a Bitwise AVAX ETF and accumulation by AVAX One Technology suggest increased institutional interest.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is trending amid speculation that cannabis could be reclassified, potentially easing tax burdens and banking restrictions for cannabis companies. The community is discussing potential price targets and whether this rally has staying power, with some citing historical runs and short squeeze potential. However, some caution against hype, noting the reverse stock split and potential for dilution.

Yee is a community based memecoin with one mission: to fight Pepe again. Made to honor the iconic meme rivalry we all know and love.  The Yee Legend  [Filed by: Yee’s Archivist & Legal Representative]  There’s something the meme world refuses to talk about: Pepe the Frog stole Yee the Dino’s entire launch plan.  Yee had been preparing for his comeback for months, but Pepe launched two weeks earlier, hijacking Yee’s concept and selling it as his own.  The charges? Meme theft, intellectual forgery, and historical erasure.  Yee’s official contract was filed in April 2023, right after Pepe’s surprise drop. This wasn’t timing—it was theft. The archives are about to open, and history is about to be corrected

Yee Token

Yee Token is trending as community members rally behind the token's potential within the Ethereum ecosystem, citing a long-term prophecy and strong community support. Social media buzz suggests growing confidence and anticipation for significant expansion, with some drawing comparisons to other successful meme coins. The community emphasizes the token's role in the broader ETH narrative, attracting attention from traders.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FCEL is trending as investors discuss its potential role in powering AI data centers using natural gas and carbon capture technology, particularly following positive mentions from ExxonMobil's recent earnings call. Community members are weighing the company's prospects against competitors like Bloom Energy, with some anticipating significant upside if FCEL secures major contracts in the expanding AI energy market. Discussions also include the stock's volatile history and the impact of past dilutions on its current valuation.

Pump Mind Virus is a Pure Meme with a long term vision. We are building for the future while making no promises about the present. The project aims to bring the spirit of community memes back to the Solana ecosystem. We do that with engaging content and memes. Culture through community. Viral spread by word of mouth.  And most importantly, by not using the fake hype machine that has come to dominate the meme coin landscape.

PumpMindVirus

PumpMindVirus ($PMV) is trending as its community rallies around its meme-focused culture and energetic online presence, emphasizing the "infection" and "pressure" it brings to the Solana ecosystem. The community is actively spreading memes and expressing excitement about its potential, aiming to bring fun and energy to the crypto space, with some even touting it as a top meme coin for 2026. Discussions highlight the coin's strong community and the "viral" spread of its memes.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

MSOS is trending as investors react to speculation around potential federal cannabis policy changes, including a possible executive order from President Trump. Community members are discussing the implications of rescheduling for US cannabis companies and whether this time could be different after years of false starts. Talk centers on potential catalysts like the Supreme Court taking up the cannabis case and the impact on profitability due to tax code changes.

Advisorshares Trust - AdvisorShares MSOS 2x Daily ETF

AdvisorShares MSOS Daily Leveraged ETF

MSOX is trending as traders discuss the potential impact of cannabis rescheduling, with some citing Trump's recent comments as a possible catalyst. The community is weighing the risks and rewards of this leveraged ETF, with many expressing confidence in a sector-wide rally. However, some traders remain cautious, pointing to historical volatility and potential reverse splits.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Innate Pharma Releases Its 2026 Financial Calendar

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today released its 2026 financial calendar: March 26, 2026: Publication of 2025 financial statements May...

Innate Pharma (OTCMKTS:IPHYF) Shares Down 0.2% - Time to Sell?

Innate Pharma (OTCMKTS:IPHYF) Shares Down 0.2% - Here's Why...

Innate Pharma (NASDAQ:IPHA) Stock Price Up 3.7% - Should You Buy?

Innate Pharma (NASDAQ:IPHA) Trading 3.7% Higher - Here's Why...

Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025

Regulatory News: Pursuant to the article L. 233-8 II of the French Code de Commerce and the article 223-16 of the French stock-market authorities (Autorit des Marchs Financiers, or AMF) General...

Innate Pharma to Present at Jefferies Global Healthcare Conference

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announces its participation in the Jefferies Global Healthcare Conference 2025. Members of its...

Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced its business update and financial results for the first nine months of 2025. This quarter...

<ul class="summary-bullets"><li>The company said that the planned confirmation late-stage trial is designed to demonstrate the efficacy of Lacutamab in certain patients with Sézary syndrome and Mycosis fungoides.</li><li>The primary goal of the study is to gauge progression-free survival.&nbsp;</li><li>The FDA reviewed the protocol of the trial with no further comments, the company further noted.&nbsp; &nbsp;</li></ul>Shares of Innate Pharma SA (IPHA) soared 13% in the premarket session on Monday after the company said that the U.S. Food and Drug Administration had cleared a confirmatory late-stage trial of Lacutamab in cutaneous T-cell lymphomas to proceed.Cutaneous T-cell lymphoma (CTCL) is a rare type of non-Hodgkin lymphoma that affects the skin. Symptoms include patches, plaques, or tumors on the skin that can be itchy and may resemble eczema or psoriasis.<h2 class="st-heading-2">About the Late-Stage Confirmatory Trial</h2>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251109757297/en/Innate-Pharma-Announces-FDA-Clearance-to-Proceed-With-TELLOMAK-3-a-Confirmatory-Phase-3-Trial-of-Lacutamab-in-CTCL">said</a> that the planned confirmation late-stage trial is designed to demonstrate the efficacy of Lacutamab in patients with Sézary syndrome and Mycosis fungoides, who failed at least one prior line of systemic therapy. Both Sézary syndrome and Mycosis fungoides are types of cutaneous T-cell lymphomas.The primary goal of the study is to gauge progression-free survival or the length of time a patient lives with a disease, such as cancer, without it getting worse, which can include time when the cancer is stable or cured.The company now intends to initiate the confirmatory trial in the first half of 2026. The FDA reviewed the protocol of the trial with no further comments, the company further noted.In a mid-stage trial, Lacutamab demonstrated durable activity, a favorable safety profile, and improvements in patients’ quality of life.“...this milestone brings us one step closer to our next goal, submitting for accelerated approval in Sézary syndrome once the Phase 3 trial is underway,” CEO Jonathan Dickinson said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IPHA">IPHA stock</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:623/63;" src="data:image/png;base64,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" width="623" height="63" alt="IPHA's Sentiment Meter and Message Volume as of 6:25 a.m. ET on Nov. 10, 2025 | Source: Stocktwits"><figcaption>IPHA's Sentiment Meter and Message Volume as of 6:25 a.m. ET on Nov. 10, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user recommended buying the stock under $3.<stembedurl>https://stocktwits.com/Iiii1ii/message/635561240</stembedurl>Another cheered the news as significant and positive.<stembedurl>https://stocktwits.com/StockNews_Live/message/635557846</stembedurl>IPHA stock is down by 4% this year and over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/us-lawmakers-reportedly-urge-ceo-to-end-union-busting-practices/cLPcLtxREcz">Starbucks Faces Political Heat: US Lawmakers Reportedly Urge CEO To End 'Union Busting’ Practices</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

IPHA Stock Soars Pre-Market After FDA Clears Late-Stage Trial For Lacutamab In Rare Skin Cancers

Shares of Innate Pharma SA (IPHA) soared 13% in the premarket session on Monday after the company said that the U.S. Food and Drug Administration had cleared a confirmatory late-stage trial of Lacutamab in cutaneous T-cell lymphomas to proceed.

Equity

The company now intends to initiate the confirmatory trial in the first half of 2026.


Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL

RegulatoryNews: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the...

Innate Pharma (IPHA) Projected to Post Quarterly Earnings on Thursday

Innate Pharma (NASDAQ:IPHA) will be releasing earnings before the market opens on Thursday, November 13. (View Earnings Report at...

Innate Pharma (IPHA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

After losing some value lately, a hammer chart pattern has been formed for Innate Pharma (IPHA), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. Its product pipeline includes Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.

IPHA
Innate Pharma

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IPHA News

IPHAInnate Pharma